Kala Pharmaceuticals (KALA) Tops Q1 EPS by 19c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021 7:01 AM EDT-- Achieved $3.3 Million in Net Revenue in First Quarter --
-- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives --
-- New Credit Facility Provides up to $125M --
-- Cash Runway Projected for at Least Two Years --
-- Conference Call and Webcast at 8:00 a.m. ET --
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the discovery, development... More
